Finch Therapeutics Group, Inc., (FNCH) News
Filter FNCH News Items
FNCH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FNCH News Highlights
- FNCH's 30 day story count now stands at 2.
- Over the past 13 days, the trend for FNCH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIOL and MD are the most mentioned tickers in articles about FNCH.
Latest FNCH News From Around the Web
Below are the latest news stories about Finch Therapeutics Group Inc that investors may wish to consider to help them evaluate FNCH as an investment opportunity.
Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines SummitSOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a panel discussion at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 3:15 pm ET. A |
Finch Therapeutics Announces Additions to Senior Leadership TeamBryan Gillis, MBA, appointed Chief Technology OfficerAlka Batycky, PhD, appointed Chief Development OfficerHoward Franklin, MD, MBA, appointed Senior Vice President, Late-Stage Development and GI Therapeutic Area Lead SOMERVILLE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biol |
First Midwest Bank Trust Division Buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares ...Joliet, IL, based Investment company First Midwest Bank Trust Division (Current Portfolio) buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares Russell Mid-Cap ETF, ISHARES TRUST, Aurinia Pharmaceuticals Inc, sells Iovance Biotherapeutics Inc, Consumer Discretionary Select Sector SPDR, AT&T Inc, Avis Budget Group Inc, Cerus Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Midwest Bank Trust Division. |
Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum DisorderSOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ: FNCH ), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Patent and Trademark Office has issued two new patents covering the company''s FIN-211 enriched consortia microbiome product candidate in development for children with autism spectrum disorder (ASD) and significant gastrointestinal (GI) symptoms. The company''s intellectual property portfolio now includes 59 issued U.S. and foreign patents with more than 130 patent applications pending. The first patent (U.S. Patent No. 11,202,808) covers key technologies involved ... |
Finch Therapeutics gets 2 US patents for FIN-211 to treat autism spectrum disorderNo summary available. |
Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect ConferenceSOMERVILLE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a corporate overview at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 am ET. I |
Finch Therapeutics up 10% following large insider buyNo summary available. |
Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Director Nicholas Haft Acquires 63,850 SharesFinch Therapeutics Group, Inc. (NASDAQ:FNCH) Director Nicholas Haft purchased 63,850 shares of the business’s stock in a transaction on Monday, December 20th. The shares were acquired at an average price of $10.18 per share, for a total transaction of $649,993.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which […] |
Trade Alert: The Independent Director Of Finch Therapeutics Group, Inc. (NASDAQ:FNCH), Nicholas Haft, Has Just Spent US$650k Buying 1.6% More SharesFinch Therapeutics Group, Inc. ( NASDAQ:FNCH ) shareholders (or potential shareholders) will be happy to see that the... |
Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal OfficerSOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the promotion of Joseph Vittiglio, JD, to Chief Business and Legal Officer. Mr. Vittiglio has more than 25 years of experience leading strategic transactions within the life sciences indus |